CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma

被引：18

作者：

Ali C.W. ^{[1
,3
]}

Kaye T.F. ^{[1
]}

Adamson D.J.A. ^{[1
]}

Tait I.S. ^{[2
]}

Polignano F.M. ^{[2
]}

Highley M.S. ^{[1
]}

机构：

[1] Department of Cancer Medicine, Ninewells Hospital

[2] Department of Surgery, Ninewells Hospital

[3] Flat 20 Caird House, Dundee DD36TU

来源：

Journal of Gastrointestinal Cancer | 2007年 / 38卷 / 2-4期

关键词：

CA; 19-9; antigen; Cholangiocarcinoma; Pancreatic neoplasms;

D O I：

10.1007/s12029-008-9019-x

中图分类号：

学科分类号：

摘要：

Background: The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear. Aim of study: To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study. Methods: A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma. Results: Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of 20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2-23.5) compared to 7.6+ months (range 4.0-14.7) in those without such a change (p∈=∈0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0-41.4) vs 6.2 months (range 3.1-9.4; p∈=∈0.0075). Conclusions: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice. © 2008 Humana Press Inc.

引用

页码：108 / 114

页数：6

共 21 条

[11]

Rothenberg M.L., Abbruzzese J.L., Moore M., Portenoy R.K., Robertson J.M., Wanebo H.J., A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma, Cancer, 78, pp. 627-632, (1996)

[12]

Ferrone C.R., Finkelstein D.M., Thayer S.P., Muzikansky A., Fernandez-Del Castillo C., Warshaw A.L., Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma, J Clin Oncol, 24, pp. 2897-2902, (2006)

[13]

Ikeda M., Okada S., Tokuuye K., Ueno H., Okusaka T., Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy, Cancer, 91, 3, pp. 490-495, (2001)

[14]

Shibamoto Y., Manabe T., Ohshio G., Sasai K., Nishimura Y., Imamura M., Takahashi M., Abe M., High-dose intraoperative radiotherapy for unresectable pancreatic cancer, International Journal of Radiation Oncology Biology Physics, 34, 1, pp. 57-63, (1996)

[15]

Tempero M., Takasaki H., Metzger H.R., Pour P., Tumor antigen levels predict survival in pancreatic cancer, Proc Am Soc Clin Oncol, 8, (1989)

[16]

Maisey N.R., Norman A.R., Hill A., Massey A., Oates J., Cunningham D., CA 19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials, Br J Cancer, 93, pp. 740-743, (2005)

[17]

Rocha-Lima C.M.S., Savarese D., Bruckner H., Dudek A., Eckardt J., Hainsworth J., Yunus F., Lester E., Miller W., Saville W., Elfring G.L., Locker P.K., Compton L.D., Miller L.L., Green M.R., Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer, J Clin Oncol, 20, pp. 1182-1191, (2002)

[18]

Heinemann V., Schermuly M.-M., Stieber P., Schulz L., Jungst D., Wilkowski R., Schalhorn A., CA19-9: A predictor of response in pancreatic cancer treated with gemcitabine and cisplatin, Anticancer Res, 19, pp. 2433-2436, (1999)

[19]

Abrams R.A., Grochow L.B., Chakravarthy A., Sohn T.A., Zahurak M.L., Haulk T.L., Ord S., Hruban R.H., Lillemoe K.D., Pitt H.A., Cameron J.L., Yeo C.J., Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels, Int J Radiat Oncol Biol Phys, 44, pp. 1039-1046, (1999)

[20]

Kau S.-H., Shyr Y.-M., Su C.-H., Wu C.-W., Lui W.-Y., Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers, J Am Coll Surg, 188, pp. 415-420, (1999)

← 1 2 3 →